To The Moon

1.$Pfizer(PFE)$ PFE another quarter with Covid related products tailwind turning into a FY23 headwind

4Q YoY
Revenue +2%
Net Income +47%
Dil. EPS +48%

FY23 guidance
Revenue down from $100 B to $69 B at mid-point
31% declinePFE FY23 guidanceThey did not share the Balance Sheet and Cash flow statement, we need to wait for the 10-k

But debt should have increased significantly with the Q4 acquisitions ($18.3 B)

Net debt was $1 B at the end of Q3, so I´m guessing it is back to double digits2.$AbbVie(ABBV)$ The day is here ABBV Humira has the first U.S. market competitor

The company has
• diversified with Allergan acquisition
• 2 giants in the making with Skyrizi & Rinvoq

it´s the world highest selling drug at $21 BOne important topic we will hear bout over Q4 is ABBV negotiated conditions for Humira for 2023
But we should trust management´s ability to navigate it, and they gave positive signs over Q33.$Amgen(AMGN)$ AMGN press release on Humira competition moment

"Amgen today announced AMJEVITA™ , a biosimilar to Humira®* (adalimumab), is now available in the United States. AMJEVITA was the first biosimilar to Humira approved by the U.S. FDA in 2016"

 

https://twitter.com/DividendWave/status/1620516110927020032